Please use this identifier to cite or link to this item:
Title: Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Austin Authors: Hofman, Michael S;Iravani, Amir;Nzenza, Tatenda C ;Murphy, Declan G
Affiliation: Department of Cancer Imaging, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Issue Date: Aug-2018 2018-08
Publication information: The Urologic clinics of North America 2018; 45(3): 503-524
Abstract: Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.
DOI: 10.1016/j.ucl.2018.03.016
PubMed URL: 30031469
Type: Journal Article
Subjects: PET
Prostate cancer
Prostate-specific membrane antigen
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.